FSR Advocacy Update: August 2025

Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (H.R. 4299) 

The FSR has recently signed a letter applauding the introduction of the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 (H.R. 4299). In order to continue protecting the patient-provider relationship, this bill, which, if enacted, will address the untenable Part B payment cuts to healthcare providers included in the Inflation Reduction Act (IRA), and protect Medicare beneficiaries’ access to lifesaving therapies.

Read the Letter

Request for favorable coverage of AVISE® Lupus test in Medical Policy #05-86000-22 titled “Tumor/Genetic Markers” 

Many FSR leaders also signed onto a letter sent to Florida Blue addressing a key statement in the current Florida Blue’s medical policy that includes AVISE® Lupus testing and requests consideration in covering this important test.

The statement, “The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.” does not align with the breadth and quality of published, peer-reviewed evidence.

As rheumatologists working daily to diagnose and manage systemic lupus erythematosus (SLE), we believe the data clearly demonstrate that AVISE Lupus improves net health outcomes through more accurate and timely diagnosis, better-informed treatment decisions, and reduced unnecessary healthcare utilization.

Read the Letter